{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T20:18:39Z","timestamp":1783455519274,"version":"3.55.0"},"reference-count":62,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T00:00:00Z","timestamp":1744070400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Nuclear Medicine"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1053\/j.semnuclmed.2025.03.006","type":"journal-article","created":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T17:02:23Z","timestamp":1745341343000},"page":"664-671","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Impact of PSMA PET on Radiation Oncology Planning"],"prefix":"10.1053","volume":"55","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2727-8005","authenticated-orcid":false,"given":"Simon K.B.","family":"Spohn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anca-L.","family":"Grosu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"15","key":"10.1053\/j.semnuclmed.2025.03.006_bib0001","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2403365","article-title":"Phase 3 trial of stereotactic body radiotherapy in localized prostate cancer","volume":"391","author":"Nv","year":"2024","journal-title":"New Engl J Med"},{"issue":"7","key":"10.1053\/j.semnuclmed.2025.03.006_bib0002","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1200\/JCO.20.02873","article-title":"Focal boost to the intraprostatic tumor in external beam radiotherapy for patients with localized prostate cancer: results from the FLAME randomized phase III trial","volume":"39","author":"Kerkmeijer","year":"2021","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1053\/j.semnuclmed.2025.03.006_bib0003","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1200\/JCO.20.03282","article-title":"Prostate-only versus whole-pelvic radiation therapy in high-risk and very high-risk Prostate cancer (POP-RT): outcomes from phase III randomized controlled trial","volume":"39","author":"Murthy","year":"2021","journal-title":"J Clin Oncol"},{"issue":"10338","key":"10.1053\/j.semnuclmed.2025.03.006_bib0004","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1016\/S0140-6736(21)01790-6","article-title":"The addition of androgen deprivation therapy and pelvic lymph node treatment to prostate bed salvage radiotherapy (NRG Oncology\/RTOG 0534 SPPORT): an international, multicentre, randomised phase 3 trial","volume":"399","author":"Pollack","year":"2022","journal-title":"Lancet"},{"issue":"3","key":"10.1053\/j.semnuclmed.2025.03.006_bib0005","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.eururo.2021.05.033","article-title":"Dose-intensified versus conventional-dose salvage radiotherapy for biochemically recurrent prostate cancer after prostatectomy: the SAKK 09\/10 randomized phase 3 trial","volume":"80","author":"Ghadjar","year":"2021","journal-title":"Eur Urol"},{"issue":"29","key":"10.1053\/j.semnuclmed.2025.03.006_bib0006","doi-asserted-by":"crossref","first-page":"3377","DOI":"10.1200\/JCO.22.00644","article-title":"Long-term outcomes and genetic predictors of response to metastasis-directed therapy versus observation in oligometastatic prostate cancer: analysis of STOMP and ORIOLE trials","volume":"40","author":"Deek","year":"2022","journal-title":"J Clin Oncol"},{"issue":"36","key":"10.1053\/j.semnuclmed.2025.03.006_bib0007","doi-asserted-by":"crossref","first-page":"5561","DOI":"10.1200\/JCO.23.00985","article-title":"Stereotactic body radiation therapy and abiraterone acetate for patients affected by oligometastatic castrate-resistant prostate cancer: a randomized phase II trial (ARTO)","volume":"41","author":"Francolini","year":"2023","journal-title":"J Clin Oncol"},{"issue":"10231","key":"10.1053\/j.semnuclmed.2025.03.006_bib0008","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1016\/S0140-6736(20)30314-7","article-title":"Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study","volume":"395","author":"Hofman","year":"2020","journal-title":"Lancet"},{"key":"10.1053\/j.semnuclmed.2025.03.006_bib0009","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.radonc.2019.07.005","article-title":"[(68)Ga-]PSMA-11 PET\/CT and multiparametric MRI for gross tumor volume delineation in a slice by slice analysis with whole mount histopathology as a reference standard - implications for focal radiotherapy planning in primary prostate cancer","volume":"141","author":"Bettermann","year":"2019","journal-title":"Radiother Oncol"},{"issue":"12","key":"10.1053\/j.semnuclmed.2025.03.006_bib0010","doi-asserted-by":"crossref","first-page":"2242","DOI":"10.1007\/s00259-014-2861-0","article-title":"11C-Choline PET\/pathology image coregistration in primary localized prostate cancer","volume":"41","author":"Grosu","year":"2014","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"10.1053\/j.semnuclmed.2025.03.006_bib0011","doi-asserted-by":"crossref","first-page":"5836","DOI":"10.1038\/s41598-021-85028-5","article-title":"The impact of the co-registration technique and analysis methodology in comparison studies between advanced imaging modalities and whole-mount-histology reference in primary prostate cancer","volume":"11","author":"Zamboglou","year":"2021","journal-title":"Sci Rep"},{"issue":"10","key":"10.1053\/j.semnuclmed.2025.03.006_bib0012","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.7150\/thno.15344","article-title":"(68)Ga-HBED-CC-PSMA PET\/CT versus histopathology in primary localized prostate cancer: a voxel-wise comparison","volume":"6","author":"Zamboglou","year":"2016","journal-title":"Theranostics"},{"issue":"5","key":"10.1053\/j.semnuclmed.2025.03.006_bib0013","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.eururo.2023.02.002","article-title":"Second version of the prostate cancer molecular imaging standardized evaluation framework including response evaluation for clinical trials (PROMISE V2)","volume":"83","author":"Seifert","year":"2023","journal-title":"Eur Urol"},{"issue":"4","key":"10.1053\/j.semnuclmed.2025.03.006_bib0014","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.crad.2007.05.022","article-title":"The diagnostic accuracy of CT and MRI in the staging of pelvic lymph nodes in patients with prostate cancer: a meta-analysis","volume":"63","author":"H\u00f6vels","year":"2008","journal-title":"Clin Radiol"},{"issue":"4","key":"10.1053\/j.semnuclmed.2025.03.006_bib0015","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.euo.2020.06.012","volume":"4","author":"Anttinen","year":"2021","journal-title":"Eur Urol Oncol"},{"issue":"9","key":"10.1053\/j.semnuclmed.2025.03.006_bib0016","doi-asserted-by":"crossref","first-page":"2951","DOI":"10.1007\/s00259-021-05296-1","article-title":"Prospective comparison of (18)F-PSMA-1007 PET\/CT, whole-body MRI and CT in primary nodal staging of unfavourable intermediate- and high-risk prostate cancer","volume":"48","author":"Malaspina","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"11","key":"10.1053\/j.semnuclmed.2025.03.006_bib0017","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1001\/jamaoncol.2021.3771","article-title":"Diagnostic accuracy of 68Ga-PSMA-11 PET for pelvic nodal metastasis detection prior to radical prostatectomy and pelvic lymph node dissection: a multicenter prospective phase 3 imaging trial","volume":"7","author":"Hope","year":"2021","journal-title":"JAMA Oncol"},{"issue":"24","key":"10.1053\/j.semnuclmed.2025.03.006_bib0018","doi-asserted-by":"crossref","first-page":"6300","DOI":"10.1158\/1078-0432.CCR-18-0768","article-title":"PSMA Ligand PET\/MRI for primary prostate cancer: staging performance and clinical impact","volume":"24","author":"Grubm\u00fcller","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"9","key":"10.1053\/j.semnuclmed.2025.03.006_bib0019","doi-asserted-by":"crossref","first-page":"2595","DOI":"10.7150\/thno.32376","article-title":"Radiomic features from PSMA PET for non-invasive intraprostatic tumor discrimination and characterization in patients with intermediate- and high-risk prostate cancer - a comparison study with histology reference","volume":"9","author":"Zamboglou","year":"2019","journal-title":"Theranostics"},{"issue":"5","key":"10.1053\/j.semnuclmed.2025.03.006_bib0020","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1007\/s00259-015-3257-5","article-title":"MRI versus \u2076\u2078ga-PSMA PET\/CT for gross tumour volume delineation in radiation treatment planning of primary prostate cancer","volume":"43","author":"Zamboglou","year":"2016","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"12","key":"10.1053\/j.semnuclmed.2025.03.006_bib0021","doi-asserted-by":"crossref","first-page":"2796","DOI":"10.1007\/s00259-020-04827-6","article-title":"Intraindividual comparison between (68)Ga-PSMA-PET\/CT and mpMRI for intraprostatic tumor delineation in patients with primary prostate cancer: a retrospective analysis in 101 patients","volume":"47","author":"Spohn","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"10.1053\/j.semnuclmed.2025.03.006_bib0022","doi-asserted-by":"crossref","first-page":"228","DOI":"10.7150\/thno.16638","article-title":"Comparison of 68Ga-HBED-CC PSMA-PET\/CT and multiparametric MRI for gross tumour volume detection in patients with primary prostate cancer based on slice by slice comparison with histopathology","volume":"7","author":"Zamboglou","year":"2017","journal-title":"Theranostics"},{"issue":"10","key":"10.1053\/j.semnuclmed.2025.03.006_bib0023","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.7150\/thno.15344","article-title":"68Ga-HBED-CC-PSMA PET\/CT versus histopathology in primary localized prostate cancer: a voxel-wise comparison","volume":"6","author":"Zamboglou","year":"2016","journal-title":"Theranostics"},{"key":"10.1053\/j.semnuclmed.2025.03.006_bib0024","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.600690","article-title":"Comparison of manual and semi-automatic [(18)F]PSMA-1007 PET based contouring techniques for intraprostatic tumor delineation in patients with primary prostate cancer and validation with histopathology as standard of reference","volume":"10","author":"Spohn","year":"2020","journal-title":"Front Oncol"},{"issue":"2","key":"10.1053\/j.semnuclmed.2025.03.006_bib0025","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.juro.2016.07.084","article-title":"Magnetic resonance imaging underestimation of prostate cancer geometry: use of patient specific molds to correlate images with whole mount pathology","volume":"197","author":"Priester","year":"2017","journal-title":"J Urol"},{"key":"10.1053\/j.semnuclmed.2025.03.006_bib0026","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.radonc.2019.07.002","article-title":"Validation of different PSMA-PET\/CT-based contouring techniques for intraprostatic tumor definition using histopathology as standard of reference","volume":"141","author":"Zamboglou","year":"2019","journal-title":"Radiother Oncol"},{"issue":"4","key":"10.1053\/j.semnuclmed.2025.03.006_bib0027","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1007\/s00259-020-05059-4","article-title":"Optimal (68)Ga-PSMA and (18)F-PSMA PET window levelling for gross tumour volume delineation in primary prostate cancer","volume":"48","author":"Draulans","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2025.03.006_bib0028","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2023.109774","article-title":"Deep learning based automated delineation of the intraprostatic gross tumour volume in PSMA-PET for patients with primary prostate cancer","volume":"188","author":"Holzschuh","year":"2023","journal-title":"Radiother Oncol"},{"issue":"3","key":"10.1053\/j.semnuclmed.2025.03.006_bib0029","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.eururo.2021.12.012","article-title":"Patterns of failure following external beam radiotherapy with or without an additional focal boost in the randomized controlled FLAME trial for localized prostate cancer","volume":"82","author":"Groen","year":"2022","journal-title":"Eur Urol"},{"issue":"1","key":"10.1053\/j.semnuclmed.2025.03.006_bib0030","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1186\/s12885-022-09434-2","article-title":"Feasibility, pitfalls and results of a structured concept-development phase for a randomized controlled phase III trial on radiotherapy in primary prostate cancer patients","volume":"22","author":"Spohn","year":"2022","journal-title":"BMC Cancer"},{"key":"10.1053\/j.semnuclmed.2025.03.006_bib0031","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.652678","article-title":"Influence of Urethra sparing on tumor control probability and normal tissue complication probability in focal dose escalated hypofractionated radiotherapy: a planning study based on histopathology reference","volume":"11","author":"Spohn","year":"2021","journal-title":"Front Oncol."},{"issue":"3","key":"10.1053\/j.semnuclmed.2025.03.006_bib0032","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.radonc.2017.04.021","article-title":"Evaluation of intensity modulated radiation therapy dose painting for localized prostate cancer using (68)Ga-HBED-CC PSMA-PET\/CT: a planning study based on histopathology reference","volume":"123","author":"Zamboglou","year":"2017","journal-title":"Radiother Oncol"},{"issue":"5","key":"10.1053\/j.semnuclmed.2025.03.006_bib0033","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/j.ijrobp.2022.04.020","article-title":"PSMA-PET- and MRI-based focal dose escalated radiation therapy of primary prostate cancer: planned safety analysis of a nonrandomized 2-armed phase 2 trial (ARO2020-01)","volume":"113","author":"Zamboglou","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"22","key":"10.1053\/j.semnuclmed.2025.03.006_bib0034","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13225795","article-title":"PSMA-PET\/MRI-based focal dose escalation in patients with primary prostate cancer treated with stereotactic body radiation therapy (HypoFocal-SBRT): study protocol of a randomized, multicentric phase III trial","volume":"13","author":"Zamboglou","year":"2021","journal-title":"Cancers (Basel)."},{"issue":"10323","key":"10.1053\/j.semnuclmed.2025.03.006_bib0035","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/S0140-6736(21)02437-5","article-title":"Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol","volume":"399","author":"Attard","year":"2022","journal-title":"Lancet"},{"issue":"4","key":"10.1053\/j.semnuclmed.2025.03.006_bib0036","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1056\/NEJMoa1702900","article-title":"Abiraterone for prostate cancer not previously treated with hormone therapy","volume":"377","author":"James","year":"2017","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1053\/j.semnuclmed.2025.03.006_bib0037","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1016\/j.ijrobp.2017.07.041","article-title":"Phase 1\/2 dose-escalation study of the use of intensity modulated radiation therapy to treat the prostate and pelvic nodes in patients with prostate cancer","volume":"99","author":"Reis Ferreira","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1053\/j.semnuclmed.2025.03.006_bib0038","first-page":"9","article-title":"Nodal recurrence patterns on PET\/CT after RTOG-based nodal radiotherapy for prostate cancer","volume":"22","author":"Liskamp","year":"2020","journal-title":"Clin Transl Radiat Oncol"},{"issue":"2","key":"10.1053\/j.semnuclmed.2025.03.006_bib0039","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2019-034623","article-title":"Study protocol of a randomised controlled trial of prostate radiotherapy in high-risk and node-positive disease comparing moderate and extreme hypofractionation (PRIME TRIAL)","volume":"10","author":"Murthy","year":"2020","journal-title":"BMJ Open"},{"issue":"6","key":"10.1053\/j.semnuclmed.2025.03.006_bib0040","doi-asserted-by":"crossref","first-page":"902","DOI":"10.2967\/jnumed.122.265025","article-title":"(68)Ga-PSMA PET\/CT-based atlas for prostate bed recurrence after radical prostatectomy: clinical implications for salvage radiation therapy contouring guidelines","volume":"64","author":"Sonni","year":"2023","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2025.03.006_bib0041","first-page":"130","article-title":"PEARLS - A multicentre phase II\/III trial of extended field radiotherapy for androgen sensitive prostate cancer patients with PSMA-avid pelvic and\/or para-aortic lymph nodes at presentation","volume":"37","author":"Murray","year":"2022","journal-title":"Clin Transl Radiat Oncol"},{"issue":"7","key":"10.1053\/j.semnuclmed.2025.03.006_bib0042","doi-asserted-by":"crossref","first-page":"961","DOI":"10.2967\/jnumed.120.252528","article-title":"Biochemical persistence of prostate-specific antigen after robot-assisted laparoscopic radical prostatectomy: tumor localizations using PSMA PET\/CT imaging","volume":"62","author":"Meijer","year":"2021","journal-title":"J Nucl Med"},{"issue":"12","key":"10.1053\/j.semnuclmed.2025.03.006_bib0043","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.2967\/jnumed.120.242180","article-title":"Impact of (68)Ga-PSMA-11 PET on the management of recurrent prostate cancer in a prospective single-arm clinical trial","volume":"61","author":"Fendler","year":"2020","journal-title":"J Nucl Med"},{"issue":"1","key":"10.1053\/j.semnuclmed.2025.03.006_bib0044","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.52971","article-title":"PSMA-PET\/CT findings in patients with high-risk biochemically recurrent prostate cancer with No metastatic disease by conventional imaging","volume":"8","author":"Holzgreve","year":"2025","journal-title":"JAMA Netw Open"},{"issue":"24","key":"10.1053\/j.semnuclmed.2025.03.006_bib0045","doi-asserted-by":"crossref","first-page":"7448","DOI":"10.1158\/1078-0432.CCR-19-1050","article-title":"Prostate-specific membrane antigen ligand positron emission tomography in men with nonmetastatic castration-resistant Prostate cancer","volume":"25","author":"Fendler","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.semnuclmed.2025.03.006_bib0046","article-title":"ESTRO ACROP consensus recommendation on the target volume definition for radiation therapy of macroscopic prostate cancer recurrences after radical prostatectomy","volume":"43","author":"Dirix","year":"2023","journal-title":"Clin Transl Radiat Oncol"},{"issue":"4","key":"10.1053\/j.semnuclmed.2025.03.006_bib0047","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.euo.2023.02.013","article-title":"Prostatectomy bed image-guided dose-escalated salvage radiotherapy (SPIDER): an international multicenter retrospective study","volume":"6","author":"Benziane-Ouaritini","year":"2023","journal-title":"Eur Urol Oncol"},{"issue":"1","key":"10.1053\/j.semnuclmed.2025.03.006_bib0048","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1186\/s12885-020-06911-4","article-title":"PEACE V - salvage treatment of OligoRecurrent nodal prostate cancer metastases (STORM): a study protocol for a randomized controlled phase II trial","volume":"20","author":"De Bruycker","year":"2020","journal-title":"BMC Cancer"},{"issue":"3","key":"10.1053\/j.semnuclmed.2025.03.006_bib0049","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.euo.2023.09.007","article-title":"PEACE V-salvage treatment of OligoRecurrent nodal prostate cancer metastases (STORM): acute toxicity of a randomized phase 2 trial","volume":"7","author":"Ost","year":"2024","journal-title":"Eur Urol Oncol"},{"issue":"5","key":"10.1053\/j.semnuclmed.2025.03.006_bib0050","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1001\/jamaoncol.2020.0147","article-title":"Outcomes of observation vs stereotactic ablative radiation for oligometastatic prostate cancer: the ORIOLE phase 2 randomized clinical trial","volume":"6","author":"Phillips","year":"2020","journal-title":"JAMA Oncol"},{"issue":"1","key":"10.1053\/j.semnuclmed.2025.03.006_bib0051","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.euo.2021.10.002","article-title":"Toxicity and efficacy of local ablative, image-guided radiotherapy in gallium-68 prostate-specific membrane antigen targeted positron emission tomography-staged, castration-sensitive oligometastatic prostate cancer: the OLI-P phase 2 clinical trial","volume":"5","author":"H\u00f6lscher","year":"2022","journal-title":"Eur Urol Oncol"},{"issue":"3","key":"10.1053\/j.semnuclmed.2025.03.006_bib0052","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/S1470-2045(24)00730-7","article-title":"ADT with SBRT versus SBRT alone for hormone-sensitive oligorecurrent prostate cancer (RADIOSA): a randomised, open-label, phase 2 clinical trial","volume":"26","author":"Marvaso","year":"2025","journal-title":"Lancet Oncol"},{"issue":"20","key":"10.1053\/j.semnuclmed.2025.03.006_bib0053","doi-asserted-by":"crossref","first-page":"3595","DOI":"10.1200\/JCO.23.00041","article-title":"Darolutamide plus androgen-deprivation therapy and Docetaxel in metastatic hormone-sensitive prostate cancer by disease volume and risk subgroups in the phase III ARASENS trial","volume":"41","author":"Hussain","year":"2023","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1053\/j.semnuclmed.2025.03.006_bib0054","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/S1470-2045(23)00063-3","article-title":"Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trial","volume":"24","author":"Sweeney","year":"2023","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1053\/j.semnuclmed.2025.03.006_bib0055","doi-asserted-by":"crossref","first-page":"866","DOI":"10.2967\/jnumed.119.235028","article-title":"3-Year freedom from progression after (68)Ga-PSMA PET\/CT-triaged management in men with biochemical recurrence after radical prostatectomy: results of a prospective multicenter trial","volume":"61","author":"Emmett","year":"2020","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2025.03.006_bib0056","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.898774","article-title":"Risk factors for biochemical recurrence after PSMA-PET-guided definitive radiotherapy in patients with de novo lymph node-positive prostate cancer","volume":"12","author":"Spohn","year":"2022","journal-title":"Front Oncol"},{"issue":"5","key":"10.1053\/j.semnuclmed.2025.03.006_bib0057","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.14748","article-title":"Development and validation of a multi-institutional nomogram of outcomes for PSMA-PET-based salvage radiotherapy for recurrent prostate cancer","volume":"6","author":"Zamboglou","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"16","key":"10.1053\/j.semnuclmed.2025.03.006_bib0058","doi-asserted-by":"crossref","first-page":"8027","DOI":"10.7150\/thno.61207","article-title":"Radiomics in prostate cancer imaging for a personalized treatment approach - current aspects of methodology and a systematic review on validated studies","volume":"11","author":"Spohn","year":"2021","journal-title":"Theranostics"},{"issue":"1","key":"10.1053\/j.semnuclmed.2025.03.006_bib0059","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1007\/s00259-022-05931-5","article-title":"The maximum standardized uptake value in patients with recurrent or persistent prostate cancer after radical prostatectomy and PSMA-PET-guided salvage radiotherapy-a multicenter retrospective analysis","volume":"50","author":"Spohn","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"8","key":"10.1053\/j.semnuclmed.2025.03.006_bib0060","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1007\/s00259-023-06195-3","article-title":"Development of PSMA-PET-guided CT-based radiomic signature to predict biochemical recurrence after salvage radiotherapy","volume":"50","author":"Spohn","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"6","key":"10.1053\/j.semnuclmed.2025.03.006_bib0061","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1007\/s00259-020-05111-3","article-title":"Uncovering the invisible-prevalence, characteristics, and radiomics feature-based detection of visually undetectable intraprostatic tumor lesions in (68)GaPSMA-11 PET images of patients with primary prostate cancer","volume":"48","author":"Zamboglou","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"2","key":"10.1053\/j.semnuclmed.2025.03.006_bib0062","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1007\/s00259-020-04971-z","article-title":"Machine learning-based analysis of [(18)F]DCFPyL PET radiomics for risk stratification in primary prostate cancer","volume":"48","author":"Cysouw","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"}],"container-title":["Seminars in Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001299825000340?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001299825000340?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,26]],"date-time":"2025-12-26T20:57:40Z","timestamp":1766782660000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0001299825000340"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":62,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S0001299825000340"],"URL":"https:\/\/doi.org\/10.1053\/j.semnuclmed.2025.03.006","relation":{},"ISSN":["0001-2998"],"issn-type":[{"value":"0001-2998","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of PSMA PET on Radiation Oncology Planning","name":"articletitle","label":"Article Title"},{"value":"Seminars in Nuclear Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.semnuclmed.2025.03.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}